Trials / Completed
CompletedNCT00105300
Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease Who Have Lost Response or Are Intolerant to Infliximab
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease who have been initially treated with infliximab and either lost response or discontinued its use as a result of intolerance to the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab |
Timeline
- Start date
- 2004-10-01
- First posted
- 2005-03-14
- Last updated
- 2006-08-15
Locations
56 sites across 4 countries: United States, Belgium, Canada, France
Source: ClinicalTrials.gov record NCT00105300. Inclusion in this directory is not an endorsement.